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2007-2008 Influenza Season 
Week 9, ending March 1, 2008 
 (All data are preliminary and may change as more reports are received.) 
 
Synopsis:  During week 9 (February 24 – March 1, 2008), influenza activity continued to decrease 
in the United States.   
o Two thousand four hundred one (27.2%) specimens tested by U.S. World Health 
Organization (WHO) and National Respiratory and Enteric Virus Surveillance System 
(NREVSS) collaborating laboratories were positive for influenza. 
o The proportion of deaths attributed to pneumonia and influenza was above the epidemic 
threshold for the eighth consecutive week. 
o The proportion of outpatient visits for influenza-like illness (ILI) and acute respiratory illness 
(ARI) was above national baseline levels. ILI decreased in seven of the nine regions 
compared to week 8, but remained above region-specific baselines in all nine regions.  The 
Mid-Atlantic and West North Central regions reported ARI at or above their region specific 
baselines.   
o Forty-seven states reported widespread influenza activity; three states reported regional 
influenza activity; and the District of Columbia reported local influenza activity. 
 
National and Regional Summary of Select Surveillance Components 
  Data for current week Data cumulative for the season 
  
Sentinel 
Provider 
ILI* 
DoD and 
VA ARI* 
% pos. 
for flu†
Number of  
jurisdictions 
reporting 
regional or 
widespread 
activity‡  
A 
(H1) 
A 
(H3) 
A 
Unsub-
typed 
B Pediatric Deaths 
Nation Elevated Elevated 27.2% 50 of 51  1550 3417 13824 4742 32 
New 
England Elevated Normal 25.4% 6 of 6 53 33 590 479 0 
Mid-
Atlantic Elevated Elevated 24.8% 3 of 3 71 50 700 762 4 
East North 
Central Elevated Normal 42.8% 5 of 5 128 698 482 269 4 
West 
North 
Central Elevated Elevated 31.7% 7 of 7 71 102 1683 480 4 
South 
Atlantic Elevated Normal 33.5% 8 of 9 278 1307 3557 875 3 
East 
South 
Central Elevated Normal 45.1% 4 of 4 29 493 64 22 5 
West South 
Central Elevated Normal 30.8% 4 of 4 87 337 5428 924 6 
Mountain Elevated Normal 24.5% 8 of 8 387 270 719 560 2 
Pacific Elevated Normal 17.0% 5 of 5 446 127 601 371 4 
* Elevated means the % of visits for ILI or ARI is at or above the national or region-specific baseline 
† National data are for current week; regional data are for the most recent three weeks 
‡ Includes all 50 states and the District of Columbia 
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Laboratory Surveillance:  During week 9, WHO and NREVSS laboratories reported 8,814 
specimens tested for influenza viruses, 2,401 (27.2%) of which were positive, including 54 influenza 
A (H1) viruses, 327 influenza A (H3) viruses, 1,280 influenza A viruses that were not subtyped, and 
740 influenza B viruses.   
 
Since September 30, 2007, WHO and NREVSS laboratories have tested a total of 138,546 
specimens for influenza viruses and 23,533 (17.0%) were positive. Among the 23,533 influenza 
viruses, 18,791 (79.8%) were influenza A viruses and 4,742 (20.2%) were influenza B viruses.  
Four thousand nine hundred sixty-seven (26.4%) of the 18,791 influenza A viruses have been 
subtyped: 1,550 (31.2%) were influenza A (H1) viruses and 3,417 (68.8%) were influenza A (H3) 
viruses. 
 
Although influenza A (H1) viruses predominated through mid-January, an increasing proportion of 
subtyped influenza A viruses are influenza A (H3) viruses. Influenza A (H3) viruses have been 
reported more frequently than influenza A (H1) viruses since week 4 (January 20-26), and during 
week 6 (February 3-9), influenza A (H3) became the predominant virus for the season overall.  This 
season influenza A (H3) viruses have been reported more frequently than A (H1) viruses nationally, 
as well as in five of the nine surveillance regions (East North Central, East South Central, South 
Atlantic, West North Central, and West South Central).  Influenza A (H1) viruses have 
predominated circulation this season in the remaining four regions (Mid-Atlantic, Mountain, New 
England, and Pacific). 
U.S. WHO/NREVSS Collaborating Laboratories
National Summary, 2007-08
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Composition of the 2008-09 Influenza Vaccine:  WHO and FDA have recommended that the 
2008-09 trivalent influenza vaccine for the Northern Hemisphere contain A/Brisbane/59/2007-like 
(H1N1), A/Brisbane/10/2007-like (H3N2), and B/Florida/4/2006-like viruses.  All three components 
have been changed from the 2007-08 Northern Hemisphere vaccine formulation.  
A/Brisbane/10/2007-like (H3N2) and B/Florida/4/2006-like viruses are currently included in the 2008 
Southern Hemisphere vaccines.  This recommendation was based on surveillance data related to 
epidemiology and antigenic characteristics, serological responses to 2007-08 vaccines, and the 
availability of candidate strains and reagents. 
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Antigenic Characterization:  CDC has antigenically characterized 366 influenza viruses [191 
influenza A (H1N1), 86 influenza A (H3N2), and 89 influenza B viruses] collected by U.S. 
laboratories since September 30, 2007. 
 
Influenza A (H1N1) [191] 
• One hundred forty-seven (77%) of the 191 viruses were characterized as A/Solomon 
Islands/3/2006-like, the influenza A (H1N1) component of the 2007-08 influenza 
vaccine for the Northern Hemisphere and the 2008 influenza A (H1N1) component 
for the Southern Hemisphere. 
• Nineteen (10%) of the 191 viruses showed somewhat reduced titers with antisera 
produced against A/Solomon Islands/3/2006. 
• Twenty-five (13%) of the 191 viruses were characterized as A/Brisbane/59/2007-like. 
A/Brisbane/59/2007 is a recent genetic/antigenic variant which evolved from 
A/Solomon Islands/03/2006. An A/Brisbane/59/2007-like virus is the WHO 
recommended strain for the 2008-09 Northern Hemisphere vaccine formulation. 
Influenza A (H3N2) [86] 
• Twelve (14%) of the 86 viruses were characterized as A/Wisconsin/67/2005-like, the 
influenza A (H3N2) component of the 2007-08 influenza vaccine for the Northern 
Hemisphere. 
• Sixty-seven (78%) of the 86 viruses were characterized as A/Brisbane/10/2007-like.  
A/Brisbane/10/2007-like viruses are a recent antigenic variant which evolved from, 
but are antigenically distinct from, A/Wisconsin/67/2005-like viruses.  
A/Brisbane/10/2007-like virus is the recommended influenza A (H3N2) component 
for the 2008 Southern Hemisphere and 2008-09 Northern Hemisphere vaccines. 
• Seven (8%) of the 86 viruses showed somewhat reduced titers with antisera 
produced against A/Wisconsin/67/2005 and A/Brisbane/10/2007. 
 
Influenza B (B/Victoria/02/87 and B/Yamagata/16/88 lineages) [89] 
Victoria lineage [6] 
• Six (7%) of the 89 influenza B viruses characterized belong to the B/Victoria lineage 
of viruses. 
o Four (67%) of these 4 viruses were characterized as B/Ohio/01/2005-like. 
The recommended influenza B component for the 2007-08 influenza vaccine 
is a B/Malaysia/2506/2004-like virus, belonging to the B/Victoria lineage.  
B/Ohio/01/2005 is a recent B/Malaysia/2506/2004-like reference strain. 
o Two (33%) of these 4 viruses showed somewhat reduced titers with antisera 
produced against B/Ohio/01/2005 and B/Malaysia/2506/2004.  
Yamagata lineage [83] 
• Eighty-three (93%) of the 89 influenza B viruses characterized belong to the 
B/Yamagata lineage of viruses.   
o Eighty-two (99%) of these 83 viruses were identified as B/Florida/04/2006-
like, the recommended influenza B component for the 2008-09 Northern 
Hemisphere vaccine formulation. 
o One (1%) of these 83 viruses showed a somewhat reduced titer with 
antiserum produced against B/Florida/04/2006.  
 
These data indicate similarities and differences between a sample of circulating strains and this 
year's vaccine strains as determined by laboratory studies. Clinical vaccine effectiveness cannot be 
accurately predicted using these data, and in previous years, influenza vaccination has been shown 
to provide measurable protection against influenza illness and influenza-related complications, even 
when vaccine strains are antigenically distinct from circulating strains. 
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Antiviral Resistance: In the United States, two groups of antiviral drugs have been approved by 
FDA for use in treating or preventing influenza virus infections.  These two groups of antiviral drugs 
are: neuraminidase inhibitors (oseltamivir and zanamivir) and adamantanes (amantadine and 
rimantidine). A description of these drugs can be found at: 
http://www.cdc.gov/flu/protect/antiviral/index.htm.  
 
Neuraminidase Inhibitor Antiviral Drugs:  Of the 743 influenza A and B viruses from the 
United States tested for antiviral resistance so far this season, 45 (6.1%) have been found to 
be resistant to oseltamivir.  Currently all of the resistant viruses are H1N1 viruses, with 45 
(8.7%) of 519 H1N1 viruses tested exhibiting a genetic mutation that confers oseltamivir 
resistance.  All tested viruses retain their sensitivity to zanamivir.  Additional information on 
antiviral resistance can be found at: http://www.cdc.gov/flu/about/qa/antiviralresistance.htm 
 
Adamantane Antiviral Drugs: Resistance to the adamantanes continues to be high.  
Among 511 influenza A viruses tested, 111 (21.7%) are resistant to adamantanes, including 
98.9% of H3N2 viruses and 4.3% of H1N1 viruses.  The adamantanes are not effective 
against influenza B viruses.   
 
Based on the level of oseltamivir resistance observed in only one influenza subtype, H1N1, 
and persisting high levels of resistance to the adamantanes in both H3N2 and H1N1 
viruses, CDC continues to recommend the use of oseltamivir and zanamivir for the 
treatment or prevention of influenza.  Use of amantadine or rimantadine is not 
recommended.  Guidance on influenza antiviral use can be found at: 
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5606a1.htm 
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Pneumonia and Influenza (P&I) Mortality Surveillance:  During week 9, 8.9% of all deaths 
reported through the 122 Cities Mortality Reporting System were reported as due to P&I. This 
percentage is above the epidemic threshold of 7.2% for week 9.  Including week 9, P&I mortality 
has been above epidemic threshold for eight consecutive weeks. 
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Influenza-Associated Pediatric Mortality: Nine influenza-associated pediatric deaths were 
reported to CDC during week 9 [GA (2), IA (3), MN, MS, NY, and OH].  One of these deaths 
occurred during the 2006-07 season, bringing the total number of cases occurring during that 
season to 75. Since September 30, 2007, CDC has received a total of 32 reports of influenza-
associated pediatric deaths that occurred during the current season.   
Number of Influenza-Associated Pediatric Deaths
by Week of Death:
2005-06 season to present
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Influenza-Associated Pediatric Hospitalizations:  Laboratory-confirmed influenza-associated 
pediatric hospitalizations are monitored in two population-based surveillance networks: the New 
Vaccine Surveillance Network (NVSN) and the Emerging Infections Program (EIP).  These two 
systems provide updates of surveillance data every two weeks.  As a result of differing dates for 
initiating surveillance in the 2007-08 season, these updates occur on alternating weeks.  
During November 4, 2007-February 23, 2008, the preliminary laboratory-confirmed influenza-
associated hospitalization rate reported by the NVSN for children 0-4 years old was 3.48 per 
10,000.   
NVSN Influenza Laboratory-Confirmed Cumulative Hospitalization 
Rates for Children 0 - 4 Years, 2007- 08 and Previous 2 Seasons
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During September 30 – February 16, 2008, the preliminary laboratory-confirmed influenza-
associated hospitalization rate reported by the EIP for children 0–17 years old was 0.57 per 10,000.  
For children aged 0-4 years and 5-17 years, the rate was 1.54 per 10,000 and 0.18 per 10,000, 
respectively. 
EIP Influenza Laboratory-Confirmed Cumulative Hospitalization 
Rates for Children Aged 0-4 and 5-17 yrs, 2007-2008 and 
Previous 2 Seasons
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Outpatient Illness Surveillance:  Nationwide during week 9, 4.8% of outpatient visits reported 
through the U.S. Influenza Sentinel Provider Surveillance Network were due to influenza-like illness 
(ILI), which is above the national baseline of 2.2%.  On a regional level, the percentage of visits for 
ILI decreased in seven of the nine regions compared to last week and ranged from 3.1% to 8.9%.  
All nine regions reported ILI above their region-specific baselines.  
Starting in week 5, New York City began reporting ILI data collected electronically from emergency 
departments city-wide, adding approximately 60,000 additional patient visits per week to the U.S. 
Influenza Sentinel Provider Surveillance Network.  Retrospective reports were submitted for all 
earlier weeks this season.  While this change increases the total patient visits per week by 
approximately 15%, it is not expected to influence the national ILI outpatient visit percentage after 
population weighting, but may have a larger impact on the Mid-Atlantic regional ILI percentage. 
During week 9, 3.2% of patient visits to Department of Veteran’s Affairs (VA) and Department of 
Defense (DoD) outpatient treatment facilities were for acute respiratory illness (ARI), which was at 
the national baseline of 3.2%.  On a regional level, the percentage of visits for ARI ranged from 
1.8% to 3.8%, and was at or above the region-specific baselines in two of the nine regions (Mid-
Atlantic and West North Central).  The percentage of visits reported for ARI was at or above age-
specific baselines in the 5-17 years, 18-49 years, 50-64 years, and >64 years age groups.   
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Percentage of Visits for ILI & ARI Reported
by Sentinel Providers and BioSense Outpatient Facilities,
National Summary
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Percentage of Visits for ARI by Age Group Reported by 
DoD/VA Outpatient Clinics - National Summary
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Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists: During 
week 9 the following influenza activity was reported: 
• Widespread activity was reported by 47 states (Alabama, Alaska, Arizona, Arkansas, 
California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, 
Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Michigan, Minnesota, 
Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New York, North 
Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South 
Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, 
Wisconsin, West Virginia, and Wyoming). 
• Regional activity was reported by three states (Massachusetts, Mississippi, and New 
Mexico). 
• The District of Columbia reported local influenza activity. 
 
 
 
 
A description of surveillance methods is available at: http://www.cdc.gov/flu/weekly/fluactivity.htm 
 
Report prepared: March 7, 2008.
  
   
